- Mechanism
- Stimulates insulin secretion and suppresses appetite
- Typical research dose
- 2.5 mg to 15 mg weekly subcutaneous
- Route
- subcutaneous
- Half-life
- ~5 days (116 hours)
- Legal status
- FDA Approved
Overview
Tirzepatide is an innovative, FDA-approved synthetic peptide that functions as a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By simultaneously targeting these two critical incretin pathways, the Tirzepatide peptide significantly enhances glycemic control, suppresses appetite, and promotes substantial reductions in body weight. This dual-action approach matters because it offers unprecedented efficacy in managing type 2 diabetes and obesity, frequently outperforming single-receptor agonists in clinical trials like SURPASS and SURMOUNT.
Potential Benefits
- Substantial Weight Loss: Clinical trials demonstrate that Tirzepatide significantly reduces body weight and fat mass in individuals with obesity or overweight Look M et al., 2025.
- Superior Glycemic Control: The peptide effectively lowers HbA1c levels in patients with type 2 diabetes, often achieving better glycemic targets than placebo or insulin glargine Dahl D et al., 2022.
- Appetite Suppression: Tirzepatide reduces overall energy intake and suppresses appetite by delaying gastric emptying and signaling satiety in the brain Heise T et al., 2023.
- Improved Body Composition: Weight reduction achieved with this dual agonist is characterized by a favorable decrease in fat mass while preserving lean muscle tissue Look M et al., 2025.
- Potential Cardiovascular Benefits: Ongoing research suggests that the metabolic improvements from Tirzepatide may translate to reduced cardiovascular risk factors in vulnerable populations ClinicalTrials.gov, NCT07096063.
Where to Buy Tirzepatide
Guru Peptides
View →Research compound. Tirzepatide is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Nausea and vomiting, particularly during dose escalation.
- Diarrhea or constipation affecting gastrointestinal motility.
- Decreased appetite leading to potential unintended caloric deficits.
- Injection site reactions, including mild redness or itching.
- Fatigue or mild dizziness associated with rapid weight loss.
Rare or serious side effects:
- Pancreatitis (inflammation of the pancreas) requiring immediate medical attention.
- Gallbladder disease, including gallstones or cholecystitis.
- Risk of thyroid C-cell tumors, based on rodent studies (black box warning).
- Severe hypoglycemia when combined with insulin or sulfonylureas.
Tirzepatide is FDA-approved but should only be used under medical supervision. Consult a qualified healthcare provider before use.
Mechanism of Action
Dual receptor activation defines the unique molecular mechanism of the Tirzepatide peptide. It functions as an imbalanced and biased dual agonist, binding to both GIP and GLP-1 receptors with a higher affinity for GIP compared to native hormones Willard FS et al., 2020. This synergistic activation enhances glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriate glucagon release.
Metabolic regulation extends beyond the pancreas, as Tirzepatide profoundly influences central appetite pathways and gastric motility. By slowing gastric emptying and signaling satiety in the hypothalamus, it drastically reduces energy intake and promotes fat mass reduction Heise T et al., 2023. The combined GIP and GLP-1 activity creates a compounded metabolic effect that drives superior weight loss and glycemic control compared to GLP-1 monotherapies.
Origin & History
Synthetic development of Tirzepatide was spearheaded by Eli Lilly and Company to address the limitations of single-target incretin therapies. Researchers engineered the 39-amino acid peptide sequence to mimic native GIP while incorporating a C20 fatty diacid moiety, which extends its half-life to approximately 5 days and allows for once-weekly subcutaneous administration. This structural innovation marked a significant milestone in peptide engineering for metabolic diseases.
Regulatory milestones for Tirzepatide include its initial FDA approval in 2022 under the brand name Mounjaro for the treatment of type 2 diabetes FDA Label. Following the highly successful SURMOUNT clinical trials demonstrating unprecedented weight loss efficacy, the FDA subsequently approved it in 2023 under the brand name Zepbound specifically for chronic weight management FDA Label. Today, it remains a cornerstone therapy in obesity and diabetes management Sinha R et al., 2023.